• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Two Medication Classes Reduce CV, Liver Events in Persons with T2D, MASLD: Daily Dose

Two Medication Classes Reduce CV, Liver Events in Persons with T2D, MASLD: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from 2 analyses presented at ENDO 2024, the Endocrine Society's annual meeting, held June 1-4 in Boston, Massachusetts.

The study

Researchers examined the cardiovascular (CV) and hepatic effectiveness and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 inhibitors (SGLT-2is) in patients with type 2 diabetes (T2D) and known metabolic dysfunction-associated steatotic liver disease (MASLD). They conducted 2 weighted cohort studies in this patient population who initiated therapy with either GLP-1RA (n=13 666), SGLT-2i (n=11 108), or DDP-4i (n=17 084). They used pooled data from Medicare documented between 2013 and 2020 and a large US health insurance database from 2013 to 2022.

The findings

GLP-1RAs and SGLT-2is associated with fewer CV events. Researchers observed that compared with DPP-4i treatment, the HR for the primary CV outcome associated with GLP-1RA agents was 0.67 (95% CI 0.56-0.81), which corresponds to an incidence rate difference (IRD) per 1000 person-years of -21.6 (95% CI 26.7 to -16.6). They also noted CV benefits for SGLT-2i use compared with DPP-4i use, with an HR for the primary CV outcome of 0.82 (95% CI 0.70-0.96) and an IRD of -11 (95% CI -16.2 to -5.8).

GLP-1RAs lowered serious liver events. Investigators noted that GLP-1RAs reduced severe liver events compared to DPP-4is, with an HR for the primary hepatic outcome of 0.47 (95% CI 0.25-0.90) and an IRD of -2.1 (95% CI -3.4 to -0.9). Among the SGLT-2i arm, the HR was 0.81 (95% CI 0.45-1.44) and an IRD of -1.1 (95% CI -2.4 to 0.3).

Authors' comment

"An increasing amount of people live with type 2 diabetes, and a significant proportion of these individuals also struggle with MASLD. Understanding which medications can effectively manage these conditions and prevent severe complications is crucial for their health and quality of life."

Click here for more details.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.